Ahmad Masri, MD, MS, is the director of the Hypertrophic Cardiomyopathy Center at Oregon Health and Science University.
Open-Label Study Finds Aficamten Could Help Most oHCM Patients Avoid Surgery
Ahmad Masri, MD, MS, discusses data from the FOREST-HCM trial examining effects of aficamten in patients with oHCM eligible for septal reduction therapy at baseline.
Read More
Recent Advances Have Improved Prognosis in ATTR-CM Patients, with Ahmad Masri, MD, MS
Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.